14 completed, 3 withdrawn, 2 recruiting, 2 terminated. 14 Phase 1, 13 Phase 2, 1 Early Phase 1, 1 Not applicable.
Follow this drug Literature Review of Protein Subunit Vaccines trials Research Report on Protein Subunit Vaccines
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine - Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5 | Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 55 | 2026-06-28 | 2026-07-02 |
| Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC Peptide vaccine - NSCLC Stage IV, ALK Fusion Protein Expression | Phase 1 / Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 12 | 2024-05-13 | 2026-07-28 |
| Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients Vaccines, Peptide - Acute Myeloid Leukemia, Adult | Phase 1 | Not yet recruiting | University Hospital Tuebingen | 20 | 2024-05-02 | 2024-02-09 |
| A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma Bevacizumab, Peptide Vaccine, Poly-ICLC as immune adjuvant - Glioblastoma, Glioma | Phase 2 | Withdrawn | NYU Langone Health | 2016-11-01 | 2020-01-13 | |
| iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL Peptide Vaccine, Imiquimod - Leukemia, Chronic Lymphatic | Phase 2 | Completed | University Hospital Tuebingen | 56 | 2016-10-05 | 2022-11-28 |
| Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists Peptide Vaccine (LPV7) + Tetanus peptide, PolyICLC, Resiquimod - Melanoma, Metastatic Melanoma | Phase 1 / Phase 2 | Completed | Craig L Slingluff, Jr | 50 | 2014-05-01 | 2024-02-28 |
| Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V) - Melanoma (Skin) | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 73 | 2010-08-13 | 2023-07-19 |
| Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 MART-1, NY-ESO-1, gp100:209-217(210M) - Melanoma (Skin) | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 127 | 2010-08-04 | 2023-01-18 |
| Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection peptide vaccine (AFO-18) - HIV INFECTIONS | Phase 1 | Completed | Gitte Kronborg | 11 | 2009-09-01 | 2014-03-27 |
| A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer T-cell receptor alternate reading frame protein (TARP) peptide vaccine, T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine - Prostate Specific Antigens, Prostate Neoplasms | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2009-05-11 | 2022-10-12 |
| HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas Peptide vaccine + Poly-ICLC - Astrocytoma, Oligoastrocytoma | Early Phase 1 | Completed | Ian F. Pollack, M.D. | 10 | 2009-04-01 | 2015-12-08 |
| PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment Peptide Vaccine, Poly IC-LC - Prostate Cancer | Not applicable | Completed | H. Lee Moffitt Cancer Center and Research Institute | 29 | 2008-12-02 | 2019-10-04 |
| Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Peptide vaccine, GM-CSF, PF3512676 - Intraocular Melanoma, Malignant Conjunctival Neoplasm | Phase 1 | Completed | Ahmad Tarhini | 22 | 2008-10-01 | 2017-06-22 |
| Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer peptide vaccine - Gastric Cancer | Phase 1 | Completed | Kinki University | 9 | 2008-09-01 | 2012-04-06 |
| Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients ALVAC-MART-1 vaccine, MART-1:26-35(27L) peptide vaccine, Aldesleukin - Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 50 | 2008-06-01 | 2015-10-28 |
| Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer Peptide vaccine for URLC10, Gemcitabine - Bile Duct Cancer | Phase 1 | Suspended | Akita University Hospital | 9 | 2008-02-01 | 2015-06-23 |
| Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R) Peptide Vaccine (PR1 Peptide), Peginterferon alfa-2b, Imatinib - Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 5 | 2006-12-01 | 2018-08-21 |
| Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma gp100:209-217(210M) peptide vaccine, gp100:280-288(288V) peptide vaccine, incomplete Freund's adjuvant - Melanoma (Skin) | Phase 2 | Withdrawn | Bristol-Myers Squibb | 2006-05-01 | 2013-05-15 | |
| Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides peptide vaccine, Granulocyte Macrophage Colony Stimulating Factor, Montanide ISA-51 - Renal Cell Cancer, Advanced Renal Cell Cancer | Phase 1 / Phase 2 | Unknown | University Hospital Tuebingen | 40 | 2005-05-01 | 2017-08-17 |
| Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer PSA:154-163(155L) peptide vaccine, incomplete Freund's adjuvant, laboratory biomarker analysis - Adenocarcinoma of the Prostate, Recurrent Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 32 | 2005-03-01 | 2013-01-23 |
Showing 20 of 25. Sign in to see all of them.
Melanoma (9) · Prostatic Neoplasms (4) · Neoplasms (3) · Uveal Melanoma (2) · Astrocytoma (1) · Bile Duct Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Glioblastoma (1) · Glioma (1) · HIV Infections (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1)
National Cancer Institute (NCI) (5) · University Hospital Tuebingen (4) · H. Lee Moffitt Cancer Center and Research Institute (3) · Ahmad Tarhini (1) · Akita University Hospital (1) · Bristol-Myers Squibb (1) · Craig L Slingluff, Jr (1) · Gitte Kronborg (1) · Hadassah Medical Organization (1) · Ian F. Pollack, M.D. (1) · Kinki University (1) · M.D. Anderson Cancer Center (1) · NYU Langone Health (1) · Ohio State University Comprehensive Cancer Center (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (16) · Japan (2) · Denmark (1) · Germany (1) · Israel (1) · Puerto Rico (1)
Arnulf Stenzl, Prof. (2) · Ahmad A. Tarhini, MD, MS (1) · Anders Fomsgaard, MD (1) · Craig L Slingluff, Jr., M.D. (1) · Frank Lieberman, MD (1) · Gitte Kronborg, MD (1) · H. Richard Alexander (1) · Hitoshi Shiozaki, MD (1) · Hoyoung M Maeng, M.D. (1) · Jan Gerstoft, MD (1) · Jeffrey S. Weber, MD, PhD (1) · John Roberts (1) · Jorge E. Cortes, MD (1) · Mayer Fishman, M.D., Ph.D. (1) · Nikhil I. Khushalani, M.D. (1)
PMID 19483644, PMID 22495394, PMID 23314272, PMID 23613128, PMID 24124874, PMID 24145345, PMID 34413169, PMID 36450385, PMID 39660140, PMID 42720126
2008 (1), R21CA099265 (1), R21CA133859 (1), U10CA031946 (1)